Parameter | Value | Distribution |
Transition probability from early POAG to moderate POAG (BB) | 0.0351 | Dirichlet |
Probability of staying in early POAG (BB) | 0.9585 | Dirichlet |
Transition probability from early POAG to death (BB) | 0.0064 | Dirichlet |
Transition probability from early POAG to moderate POAG (PA) | 0.0296 | Dirichlet |
Probability of staying in early POAG (PA) | 0.964 | Dirichlet |
Transition probability from early POAG to death (PA) | 0.0064 | Dirichlet |
Transition probability from moderate POAG to advanced POAG | 0.012 | Dirichlet |
Probability of staying in moderate POAG | 0.9816 | Dirichlet |
Transition probability from moderate POAG to death | 0.0064 | Dirichlet |
Transition probability from advanced POAG to severe visual impairment | 0.0103 | Dirichlet |
Probability of staying in advanced POAG | 0.9834 | Dirichlet |
Transition probability from advanced POAG to death | 0.0064 | Dirichlet |
Probability of staying in severe visual impairment | 0.9937 | Beta |
Transition probability from severe visual impairment to death | 0.0064 | Beta |
Probability of asthma (BB) | 0.006 | Beta |
Probability of no asthma (BB) | 0.994 | Beta |
Two-month discount rate | 0.0025 | - |
Relative risk for prostaglandin analogues | 0.8433 | Lognormal |
Probability of needing medication in severe visual impairment | 0.1 | Beta |
Probability of not needing medication in severe visual impairment | 0.9 | Beta |
Cost of treatment for early POAG patients who use beta blockers | 3.77 | Gamma |
Cost of treatment for early POAG patients who use prostaglandin analogues | 51.54 | Gamma |
Cost of treating asthma patients | 28.78 | Gamma |
Cost of treating moderate POAG patients | 34.91 | Gamma |
Cost of treating advanced POAG patients | 54.67 | Gamma |
Cost of treating patients with severe visual impairment | 3.77 | Gamma |
Health-related quality of life for patients with early POAG | 0.989 | Lognormal |
Health-related quality of life for patients with moderate POAG | 0.944 | Lognormal |
Health-related quality of life for patients with advanced POAG | 0.819 | Lognormal |
Health-related quality of life for patients with severe visual impairment | 0.503 | Lognormal |
Health disutility due to asthma | 0.14 | Lognormal |